Mendus
Mendus to participate in investor and industry conferences in February
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:
BIO Capital 2025
Amsterdam, The Netherlands, February 5 – 6, 2025
Mendus CEO Erik Manting will attend
Cell & Gene Therapy Manufacturing Summit 2025
Basel, Switzerland, February 12 – 14, 2025
Mendus CTO Leopold Bertea will hold a presentation about establishing large-scale manufacturing for Mendus’ lead program vididencel and participate in a panel discussion about challenges and solutions in the manufacturing and supply chain of cell therapy products
For more information, please see Cell & Gene Therapy Manufacturing Summit 2025
Biologics Manufacturing Germany
München, Germany, February 18 – 19, 2025
Mendus CTO Leopold Bertea will hold a presentation about establishing large-scale manufacturing for Mendus’ lead program vididencel and participate in a panel discussion about evolving collaboration models between biopharmaceutical companies and manufacturing organizations
For more information, please see Biologics Manufacturing Germany
Datum | 2025-02-04, kl 08:00 |
Källa | MFN |
